Table 1.
Change from baseline in glucose, insulin, and ADMA at 10, 20, 30, 60, 120, 180, and 240 min postprandial
| Treatment | Time (min) | Glucose (mg/dl) | Insulin (μU/ml) | ADMA (nmol/l) |
|---|---|---|---|---|
| HI | 10 | 5.4 ± 2.5 | 13.7 ± 3.6 | −3.3 ± 21.9 |
| LI | 10 | 6.4 ± 4.7 | 6.8 ± 4.2 | −9.1 ± 18.8 |
| VJ | 10 | 21.1 ± 4.9*† | 20.5 ± 3.2 | 9.3 ± 30.3 |
| HI | 20 | 19.7 ± 5.1 | 26.1 ± 5.2 | 97.7 ± 24.4 |
| LI | 20 | 27.2 ± 9.4 | 17.1 ± 6.0 | 66.9 ± 33.9 |
| VJ | 20 | 35.6 ± 4.7 | 42.7 ± 5.9* | −27.3 ± 22.6*† |
| HI | 30 | 33.6 ± 6.4 | 34.1 ± 5.7 | 27.1 ± 29.3 |
| LI | 30 | 39.9 ± 10.5 | 21.8 ± 6.3 | −2.0 ± 35.8 |
| VJ | 30 | 42.4 ± 7.3 | 45.1 ± 4.6 | 35.9 ± 37.6 |
| HI | 60 | 60.8 ± 12.8 | 37.9 ± 6.1 | 14.1 ± 28.4 |
| LI | 60 | 49.9 ± 7.4 | 24.8 ± 6.2 | 8.6 ± 38.3 |
| VJ | 60 | 52.4 ± 10.2 | 47.2 ± 6.9 | 43.4 ± 37.1 |
| HI | 120 | 34.6 ± 9.3 | 32.6 ± 2.8 | 3.1 ± 26.1 |
| LI | 120 | 31.2 ± 11.6 | 16.8 ± 3.9 | −27.2 ± 34.4 |
| VJ | 120 | 19.5 ± 8.8 | 31.3 ± 3.7 | −28.8 ± 33.9 |
| HI | 180 | −7.3 ± 9.1 | 17.8 ± 2.4 | −18.2 ± 33.9 |
| LI | 180 | −19.5 ± 15.3 | 1.4 ± 1.9 | −46.2 ± 27.8 |
| VJ | 180 | −7.1 ± 9.7 | 16.0 ± 2.7 | −9.9 ± 24.6 |
| HI | 240 | −37.9 ± 7.0 | 9.2 ± 1.3 | 48.2 ± 40.7 |
| LI | 240 | −46.1 ± 10.8 | −4.5 ± 0.9 | −11.3 ± 33.7 |
| VJ | 240 | −3.9 ± 6.8 | 4.8 ± 1.2* | −94.3 ± 25.2* |
Data are means ±SEM.
*P < 0.05 vs. human regular insulin.
†P < 0.05 vs. insulin lispro. (Because they are measured with different assays, lispro vs. human insulin comparisons are not presented). HI, human insulin; LI, insulin lispro; VJ, VIAject.